A detailed history of Temasek Holdings (Private) LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Temasek Holdings (Private) LTD holds 279,693 shares of NTLA stock, worth $3.07 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
279,693
Holding current value
$3.07 Million
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $5.52 Million - $7.65 Million
279,693 New
279,693 $5.75 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $2.38 Million - $3.45 Million
75,417 Added 36.92%
279,693 $8.84 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $40.1 Million - $55 Million
-397,563 Reduced 66.06%
204,276 $24.2 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $25 Million - $33.4 Million
-188,688 Reduced 23.87%
601,839 $80.7 Million
Q3 2017

Nov 14, 2017

BUY
$15.16 - $25.75 $12 Million - $20.4 Million
790,527
790,527 $19.6 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $835M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Temasek Holdings (Private) LTD Portfolio

Follow Temasek Holdings (Private) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Temasek Holdings (Private) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Temasek Holdings (Private) LTD with notifications on news.